TrialMultiple sclerosis (Houndmills, Basingstoke, England)2015

Long-term safety and efficacy of dalfampridine for walking impairment in patients with multiple sclerosis: Results of open-label extensions of two Phase 3 clinical trials.

Andrew D Goodman et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.